Evidence map›Paper›PMID 19339998›Full record

ReviewJournal of human hypertension2009

Angiotensin inhibition and malignancies: a review.

T Rosenthal, I Gavras

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of human hypertension, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 5 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Renin-angiotensin system blockade for the risk of cancer and death.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2016
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

T RosenthalDepartment of Physiology and Pharmacology, Hypertension Research Unit, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. rtalma@post.tau.ac.il
I Gavras
Boston University · USTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After an early report that patients treated with angiotensin-converting enzyme (ACE) inhibitors had a lower than expected incidence of cancers, there was a large number of publications investigating the possible pathophysiological mechanism mediating this effect, as well as population studies comparing the incidence of cancers in patients treated with agents inhibiting the renin-angiotensin system with their incidence in the general population. Several mechanisms are proposed to explain a potential anti-tumour activity of such agents in vitro in experimental animal models. However, the population studies are mostly inconclusive, although they do suggest a possible interaction between ACE genotypes and susceptibility to altered behaviour of certain tumours.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAnimalsAnticarcinogenic AgentsAntihypertensive AgentsCell Transformation, NeoplasticEvidence-Based MedicineHumansHypertensionNeoplasmsRenin-Angiotensin SystemSignal TransductionAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAnticarcinogenic AgentsAntihypertensive Agents

Identifiers

PMID19339998
OpenAlexW2010430961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.